BioPharmSignal logoBioPharmSignal

Biotech News

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook (OTLK)OutlookCommercial

Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial

Related news

OTLKOutlook2026-10-09 12:30 EST

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

OTLKOutlook2026-06-16 12:02 EST

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

TARSTarsus Pharmaceuticals2026-10-28 12:30 EST

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

LENZLenz Therapeutics Inc2026-07-06 12:15 EST

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

HROWHarrow, Inc.2026-07-01 11:00 EST

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

BLTEBelite Bio2026-08-24 20:00 EST

Belite Bio to Host Virtual Commercial Day on September 2, 2026

TARSTarsus Pharmaceuticals2026-07-13 20:05 EST

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

RHHBYRoche Holdings AG2026-10-28 06:00 EST

Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

LCTXLineage Cell Therapeutics2026-11-05 13:00 EST

Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

OCSOculis2026-11-02 07:00 EST

Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation

View all latest news

Outlook

Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...

Recent company news

OTLKOutlook2026-10-09 12:30 EST

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

OTLKOutlook2026-10-06 13:20 EST

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

OTLKOutlook2026-10-01 13:01 EST

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

OTLKOutlook2026-09-11 11:00 EST

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

OTLKOutlook2026-09-10 13:10 EST

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Stock data

Close
0.44 USD
Market cap
120.89M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States